TLDR Metaplanet’s stock has dropped 54% since mid-June despite Bitcoin’s gains The company holds 20,000 Bitcoin (worth over $2 billion) and aims for 100,000 BTC by 2026 Falling share prices threaten the company’s fundraising model based on MS warrants Metaplanet plans to raise $880 million through overseas share offerings and potentially $3.7 billion through preferred [...] The post Metaplanet Seeks $880M in Overseas Markets as Bitcoin Strategy Faces Headwinds appeared first on Blockonomi.TLDR Metaplanet’s stock has dropped 54% since mid-June despite Bitcoin’s gains The company holds 20,000 Bitcoin (worth over $2 billion) and aims for 100,000 BTC by 2026 Falling share prices threaten the company’s fundraising model based on MS warrants Metaplanet plans to raise $880 million through overseas share offerings and potentially $3.7 billion through preferred [...] The post Metaplanet Seeks $880M in Overseas Markets as Bitcoin Strategy Faces Headwinds appeared first on Blockonomi.

Metaplanet Seeks $880M in Overseas Markets as Bitcoin Strategy Faces Headwinds

TLDR

  • Metaplanet’s stock has dropped 54% since mid-June despite Bitcoin’s gains
  • The company holds 20,000 Bitcoin (worth over $2 billion) and aims for 100,000 BTC by 2026
  • Falling share prices threaten the company’s fundraising model based on MS warrants
  • Metaplanet plans to raise $880 million through overseas share offerings and potentially $3.7 billion through preferred shares
  • The company just purchased an additional 1,009 Bitcoin for approximately $110 million

Metaplanet, a Tokyo-listed company known for its aggressive Bitcoin accumulation, is facing challenges as its stock price continues to fall. The firm’s shares have plunged 54% since mid-June, even as Bitcoin gained about 2% during the same period.

This stock decline puts pressure on the company’s primary fundraising method. Metaplanet has been using a “flywheel” strategy dependent on rising share prices to secure funding through MS warrants issued to its key investor, Evo Fund.

The company currently holds 20,000 Bitcoin, purchased at an average price of 15.1 million yen per BTC. This makes Metaplanet the seventh-largest public holder of Bitcoin globally, with holdings valued at over $2 billion.

Led by former Goldman Sachs trader Simon Gerovich, Metaplanet has set ambitious goals. The company aims to grow its Bitcoin stack to 100,000 BTC by the end of 2026, and 210,000 BTC by 2027.

Alternative Fundraising Approaches

With its share-based fundraising model under stress, Metaplanet is exploring new options. On Wednesday, the company announced plans to raise approximately 130.3 billion yen ($880 million) through a public share offering in overseas markets.

Additionally, shareholders will vote Monday on whether to approve the issuance of up to 555 million preferred shares. This rare financial instrument in Japan could potentially raise as much as 555 billion yen ($3.7 billion).

Gerovich described the preferred shares as a “defensive mechanism” in an interview with Bloomberg. These shares would allow capital infusion without diluting common shareholders if the stock falls further.

The preferred shares are expected to offer up to 6% annual dividends. They will initially be capped at 25% of the firm’s Bitcoin holdings, which may appeal to Japanese investors seeking yield.

However, analysts remain cautious about this approach. Eric Benoit of Natixis stated that “the Bitcoin premium is what will determine the success of the entire strategy.” This premium—the difference between Metaplanet’s market cap and the value of its Bitcoin holdings—has dropped from over 8 times in June to just 2 times now.

Recent Bitcoin Purchases

Despite these challenges, Metaplanet continues its Bitcoin accumulation strategy. On September 1, the company purchased an additional 1,009 Bitcoin worth approximately $110 million, at an average buying price of 16.3 million yen per Bitcoin.

The company’s BTC Yield, which reflects the percentage change in the ratio of Total Bitcoin Holdings to fully Diluted Shares Outstanding, was 30.7% from July 1 to September 1, 2025. This metric was higher in the previous quarter, reaching 129.4% from April to June.

Metaplanet launched its Bitcoin accumulation strategy in April 2024. The company has reported strong earnings in recent months, with total revenue of 1.2 billion yen ($8.4 million) from April to July.

According to its latest quarterly report, Metaplanet saw a 41% surge quarter-on-quarter, with a profit of 11.1 billion yen ($75.1 million) in Q2. The company expects full-year revenue of 3.4 billion yen ($23.1 million) and operating profit of 2.5 billion yen (about $17 million).

Gerovich highlighted the growth of their Bitcoin income generation business: “Our Bitcoin income generation business has grown for 3 straight quarters. This recurring income adds resilience and supports further accumulation.”

The company has suspended Evo’s warrant exercises from September 3 to 30, preparing the way for the preferred stock issuance. Whether this shift can stabilize Metaplanet’s funding strategy remains uncertain.

Metaplanet’s adviser Eric Trump is expected to attend the firm’s shareholder meeting in Tokyo on Monday. This follows his appearance last week at the Bitcoin Asia conference in Hong Kong.

The company was recently upgraded from a small-cap to a mid-cap stock in FTSE Russell’s September 2025 Semi-Annual Review. This change earned Metaplanet inclusion in the FTSE Japan Index, following the company’s strong Q2 performance.

The post Metaplanet Seeks $880M in Overseas Markets as Bitcoin Strategy Faces Headwinds appeared first on Blockonomi.

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$95,456.07
$95,456.07$95,456.07
-1.36%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26